| Product Code: ETC069982 | Publication Date: Jun 2021 | Updated Date: Jun 2026 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The Mexico Contract Cell and Gene Therapy Manufacturing Market was estimated at USD 206 Million in 2025 and is projected to reach USD 238 Million by 2032, growing at a CAGR of 2.1% from 2026 to 2032. This growth trajectory is fueled by significant advancements in biotechnology and the rising demand for personalized medicine. With Mexico's burgeoning investment in research and development, the country is carving out a vital niche in the global biopharmaceutical manufacturing arena.
This graph highlights how the Mexico Contract Cell and Gene Therapy Manufacturing Market has steadily grown over the years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | -4.0% | Rapid growth in telecom and data center sectors |
| 2022 | 5.7% | Expansion of commercial construction activities |
| 2023 | 4.3% | Expansion of manufacturing activities |
| 2024 | 3.7% | Rising electricity demand across industries |
| 2025 | 2.4% | Expansion of transportation and logistics networks |
| 2026 | 0.9% | Expansion of commercial construction activities |
| 2027 | 2.6% | Increasing smart city development projects |
| 2028 | 2.4% | Increasing industrial automation investments |
| 2029 | 3.0% | Growing renewable energy integration projects |
| 2030 | 2.5% | Increasing industrial infrastructure investments |
| 2031 | 3.0% | Rising electricity demand across industries |
| 2032 | 3.0% | Increasing adoption of advanced technologies |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.
Recent momentum in Mexico's Contract Cell and Gene Therapy Manufacturing market highlights a unique confluence of technology and healthcare innovation. As personalized medicine continues to gain traction, the market is well-positioned for growth, though it faces hurdles that could temper its pace.
Looking ahead, the market is set to navigate challenges related to infrastructure and skilled labor. However, collaborative efforts between biopharmaceutical firms and contract manufacturing organizations are expected to drive forward the evolution of therapeutic solutions.
While the Mexico Contract Cell and Gene Therapy Manufacturing market is on an upward trajectory, several critical restraints are holding it back. A major concern is the existing infrastructure, which often lacks the state-of-the-art equipment necessary for cutting-edge production methods. Additionally, a glaring shortage of skilled professionals in critical areas such as bioprocessing and regulatory affairs limits operational capabilities. This skills gap not only impacts the current workforce but also poses a long-term challenge for industry growth, as companies strive to meet increasing production demands while maintaining compliance with stringent regulations.
The market is currently shaped by several key trends, including an intensified focus on personalized therapies and increased investment in advanced manufacturing technologies. Furthermore, partnerships between biotech firms and contract manufacturers are becoming commonplace, fostering innovation and reducing time to market for novel therapies. The regulatory landscape is also evolving, as agencies seek to streamline approval processes, making it easier for companies to navigate the complexities of bringing new products to market.
Significant growth opportunities exist in the Mexican market, particularly in expanding contract manufacturing services to support diverse therapeutic areas. The increasing global demand for personalized medicine also creates a fertile ground for investment in biomanufacturing infrastructure. With the right strategies and capital, companies can leverage Mexico's competitive labor costs and favorable government policies to establish themselves as leaders in this burgeoning sector.
The Mexican government has implemented various initiatives aimed at creating a conducive environment for contract manufacturing in the biopharmaceutical sector. These initiatives include financial incentives for research and development, as well as streamlined regulatory frameworks designed to facilitate quicker approvals for new therapies. Such policies not only attract foreign investment but also stimulate domestic companies to enhance their manufacturing capabilities.
Between 2026 and 2032, the Mexico Contract Cell and Gene Therapy Manufacturing market is poised for transformative growth. As biopharmaceutical companies continue to prioritize innovative therapeutic solutions, Mexico will likely solidify its position as a strategic manufacturing hub. The combination of government support, rising healthcare needs, and collaboration within the industry sets the stage for a robust market evolution, paving the way for breakthroughs in personalized medicine.
In the recent months leading into mid-2026, the industry has witnessed a marked increase in partnerships between biotech companies and contract manufacturers. This has led to a surge in development projects aimed at addressing unmet medical needs. Moreover, several conferences and workshops have been held to foster discussions on regulatory reforms and technological advancements, enhancing collaboration across the sector.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Mexico Contract Cell and Gene Therapy Manufacturing Market Overview |
3.1 Mexico Country Macro Economic Indicators |
3.2 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, 2022 & 2032F |
3.3 Mexico Contract Cell and Gene Therapy Manufacturing Market - Industry Life Cycle |
3.4 Mexico Contract Cell and Gene Therapy Manufacturing Market - Porter's Five Forces |
3.5 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume Share, By Vector, 2022 & 2032F |
3.6 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume Share, By Indication, 2022 & 2032F |
4 Mexico Contract Cell and Gene Therapy Manufacturing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing demand for personalized medicine and advanced therapeutics |
4.2.2 Increasing investment in research and development in the cell and gene therapy sector |
4.2.3 Favorable regulatory environment supporting cell and gene therapy manufacturing in Mexico |
4.3 Market Restraints |
4.3.1 High cost associated with cell and gene therapy manufacturing |
4.3.2 Lack of skilled workforce and infrastructure for advanced manufacturing processes in Mexico |
5 Mexico Contract Cell and Gene Therapy Manufacturing Market Trends |
6 Mexico Contract Cell and Gene Therapy Manufacturing Market, By Types |
6.1 Mexico Contract Cell and Gene Therapy Manufacturing Market, By Vector |
6.1.1 Overview and Analysis |
6.1.2 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Vector, 2022-2032F |
6.1.3 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Viral Vector, 2022-2032F |
6.1.4 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Non-viral Vector, 2022-2032F |
6.2 Mexico Contract Cell and Gene Therapy Manufacturing Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Cancer, 2022-2032F |
6.2.3 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Neurological Diseases, 2022-2032F |
6.2.4 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Hepatological Diseases, 2022-2032F |
6.2.5 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Others, 2022-2032F |
7 Mexico Contract Cell and Gene Therapy Manufacturing Market Import-Export Trade Statistics |
7.1 Mexico Contract Cell and Gene Therapy Manufacturing Market Export to Major Countries |
7.2 Mexico Contract Cell and Gene Therapy Manufacturing Market Imports from Major Countries |
8 Mexico Contract Cell and Gene Therapy Manufacturing Market Key Performance Indicators |
8.1 Percentage increase in the number of clinical trials utilizing cell and gene therapy in Mexico |
8.2 Number of partnerships between Mexican contract manufacturers and international biotech companies |
8.3 Investment in infrastructure development for cell and gene therapy manufacturing facilities in Mexico |
9 Mexico Contract Cell and Gene Therapy Manufacturing Market - Opportunity Assessment |
9.1 Mexico Contract Cell and Gene Therapy Manufacturing Market Opportunity Assessment, By Vector, 2022 & 2032F |
9.2 Mexico Contract Cell and Gene Therapy Manufacturing Market Opportunity Assessment, By Indication, 2022 & 2032F |
10 Mexico Contract Cell and Gene Therapy Manufacturing Market - Competitive Landscape |
10.1 Mexico Contract Cell and Gene Therapy Manufacturing Market Revenue Share, By Companies, 2025 |
10.2 Mexico Contract Cell and Gene Therapy Manufacturing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here